|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Determina- tion of bile acid in pharmaceutical formulations using micellar electrokinetic chromatography显示文摘 | Rodriguez VG Lucangioli SE Fernandez GC | 2000 | J Pharm Biomed Anal2000，23，23： | 1 |
| 2 | Case report:MR1 in the diagnosis of tcsticular Leydig cell tumour显示文摘 | Fernandez GC Tardaguila F Rivas C | | 0，，918： | 1 |
| 3 | Pediatric and adult forms of type Ⅰ autoimmune hepatitis in Argentina: Evidence for differential genetic predisposition显示文摘 | Pando M Larriba J Fernandez GC | 1999 | Hepatology1999，30，6： | 1 |
| 4 | Fibrinogen - CD11b/CD18interaction activates the NF- kappa B pathway and delays apoptosis in human neutrophils显示文摘 | Rubel C Gomez S Fernandez GC | 2003 | Eur J Immunol2003，33，5： | 1 |
| 5 | Fibrinogen promotes neutrophil activation and delays apoptosis显示文摘 | Rubel C Fernandez GC Dran G | 2001 | J Immunol2001，166，3： | 1 |
| 6 | Large adrenal pseudocyst mimicking cystic pheochromocytoma:excision minimising laparoscopic access显示文摘 | FARINA LA ANTON I FERNANDEZ GC | 2009 | Actas Urol Esp2009，33，8： | 1 |
| 7 | Fibrinogen promotes neutrophil activation and delays apoptosis 显示文摘 | Rubel C Fernandez GC Dran G | 2001 | J Immunol(Baltimore Md :1950)2001，166，3： | 1 |
| 8 | Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition显示文摘 | Pando M Larriba J Fernandez GC | 1999 | Hepatology1999，30，6： | 1 |
| 9 | Megestrol indueed Cushing's syndrome显示文摘 | Caparros GC ZsmbI(R)na JL Delgado Fernandez M | 2001 | Annals of Pharmacotherapy2001，35，： | 1 |
| 10 | Correlation of the blind spot size to the area of the optic disk and parapapillary atrophy显示文摘 | Jonas JB Gusek GC Fernandez MC | 1991 | Am J Ophthalmol1991，111，5： | 1 |
| 11 | Case report: MR| in the diagnosis of testicular Leydig cell tumour显示文摘 | Fernandez GC Tardagui|a F Rivas C et ' tl | 2004 | Br J Radio12004，77，： | 1 |
| 12 | Bypass graft imaging and coronary anomalies in MDCT显示文摘 | Fernandez GC | 2005 | Eur Radiol2005，15，2： | 1 |
| 13 | Bypass graft imaging and coronary anomalies in MDCT显示文摘 | Fernandez GC | 2005 | Eur Radiol2005，15，12： | 1 |
| 14 | Pediatric and adult forms of type Ⅰ autoimmune hepatitis in Argentina:Evidence for differential genetic predisposition显示文摘 | Larriba J Fernandez GC | 1999 | Hepatology1999，30，5： | 1 |
| 15 | Endogenous glucocorticoids modulate neutrophil function in a murine model of haemolytic uraemic syndrome 显示文摘 | Gomez SA Fernandez GC Camerano G | 2005 | Clin Exp Immunol2005，139，： | 1 |
| 16 | Bypass graft imaging and coronary anomalies in MDCT显示文摘 | Fernandez GC | 2005 | Eur Radiol2005，152，： | 1 |
| 17 | Determina- tion of bile acid in pharmaceutical formulations using micellar electrokinetic chromatography显示文摘 | Rodriguez VG Lucangioli SE Fernandez GC | 2000 | J Pharm Biomed Anal2000，23，23： | 1 |
| 18 | Bypass graft imaging and coronary anomalies in MDCT显示文摘 | Fernandez GC | 2005 | Eur Radiol2005，152，： | 1 |
| 19 | Prospective application of a bleeding and ischemic risks-adjusted antithrombotic protocol in elderly patients revascularized with everolimus-eluting stents:EPIC05-Sierra75 study显示文摘OBJECTIVES Elderly patients show a higher incidence of ischemic and bleeding events after percutaneous transluminal coron-ary intervention(PCI).We sought to investigate outcomes in elderly patients treated with antithrombotic strategy guided by bleeding and ischemic risks after revascularization with last generation everolimus-eluting stent(EES).METHODS Prospective multicenter registry including patients over 75 years revascularized with EES and antithrombotic ther-apy guided by clinical presentation,PCI complexity and PRECISE DAPT score.Co-primary safety endpoints were:(1)composite of cardiac death,myocardial infarction and stent thrombosis and;(2)bleeding(BARC 2-5).Primary efficacy endpoint was target lesion revascularization.A matched group of patients revascularized with current drug-eluting stents and no such tailored antith-rombotic therapy was used as control.RESULTS Finally,1064 patients were included in SIERRA-75 cohort,80.8±4.2 years,36.6%women,71%acute coronary syn-dromes(ACS)and 53.6%complex PCI.Co-primary safety endpoint of major adverse cardiovascular events was met in 6.2%,co-primary safety endpoint of bleeding in 7.8%and primary efficacy endpoint of TKLR in 1.5%.The multivariable adjusted model showed no significant association of the prescribed short/long dual antiplatelet therapy(DAPT)durations with any endpoint suggesting a well tailored therapy.No stent thrombosis reported in the subgroup with 1-3 months DAPT duration.As compared to control group,bleeding BARC 2-5 was significantly lower in SIERRA-75 group(7.4%vs.10.2%,P=0.04)as well as the net safety-efficacy endpoint(14.3%vs.18.5%,P=0.02).CONCLUSIONS In elderly population,the application of this risks-adjusted antithrombotic protocol after revascularization with last generation EES seems to be associated with an improved prognosis in terms of ischemic and bleeding outcomes. | Jose M de la Torre Hernandez Ramon Lopez Palop Jesus M Jimenez Mazuecos Pilar Carrillo Sáez Alejandro Gutierez-Barrios Eduardo Pinar Belen Cid Luis Fernandez Tamara Garcia Camarero Cristóbal Urbano-Carrillo Juan F Oteo Dominguez Victor A Jimenez Diaz Antonio EGomez Menchero Eladio Galindo Fernández Juan GCórdoba Soriano Raymundo Ocaranza Eduardo ArroyoÚcar Koldobika Garcia San Roman Silvio Leal Ginés Martínez Cáceres Jose A Linares Vicente Georgina Fuertes Ferre Xavier Carrillo Juan CRama Merchán Catia Costa Juan Sanchis Renato Fernandes Alberto Rodrigues Jose M Vegas Valle Hélder Pereira Armando Perez de Prado | 2022 | Journal of Geriatric Cardiology2022，19，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员